Laboratorios Farmaceuticos Rovi stock

ROVI · BME · EUR

Compare Laboratorios Farmaceuticos Rovi
€63.10Change from previous close: −4.54%Absolute change: −€3.00

Close · November 20, 2026

Price history

+9.55% over the period

1 year: from €57.60 (November 20, 2025) to €63.10 (November 20, 2026), +9.55%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€63.10
October 30, 2026€62.55
September 30, 2026€58.80
August 31, 2026€60.60
July 31, 2026€58.55
June 30, 2026€57.85
May 29, 2026€59.30
April 30, 2026€79.40
March 31, 2026€80.75
February 27, 2026€84.75
January 30, 2026€71.90
December 31, 2025€63.50
November 28, 2025€59.45
November 20, 2025€57.60

At a glance

  • The company

    Manufactures and markets pharmaceutical products and provides contract-manufacturing services for injectable and solid pharmaceutical forms

  • Latest results

    Quarter to June 30, 2026 · EPS €1.47

TickerLandia's take on Laboratorios Farmaceuticos Rovi

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€53.10
52-wk high€86.70

−27.22% from the 52-week high

Analysts · 9 analysts

Average target€75.22+19.21% vs. price

Buy 4 · Hold 5 · Sell 0 · Buy

TickerLandia Fingerprint: Laboratorios Farmaceuticos Rovi

Compared with similar companies: high profitability, high financial strength, and low dividend.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Laboratorios Farmaceuticos Rovi is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Laboratorios Farmaceuticos Rovi's P/E today is 23.0, in line with the median of its last 10 fiscal years (25.1; between 9.66 and 49.9 from 2016 to 2025). Laboratorios Farmaceuticos Rovi's P/E (trailing 12 months): 16.0, −17% against the median of a group of 10 similar companies (19.4).

P/E compared with its history

Compared with 10 similar companies

Laboratorios Farmaceuticos Rovi's metrics compared with similar companies
MetricLaboratorios Farmaceuticos RoviPosition in the groupBand
P/E (trailing 12 months)16.0Low
Forward P/E19.9Middle
Operating margin20.2%Middle
ROE28.7%High
Debt/equity0.13Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Laboratorios Farmaceuticos Rovi. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€191.67M

Latest quarter · Q2 2026

Net income

€75M

Latest quarter · Q2 2026

Quarterly net margin

39.1%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€3.34B
P/E
16.0
EPS
€4.08
Volume
18.65K
Daily trading
€9.17M
Dividend yield
1.52%
Last ex-dividend on July 13, 2026

How Laboratorios Farmaceuticos Rovi is changing

All results
  • Revenue grew 12.1% a year on average over the last 5 years

  • Operating margin fell from 31.0% to 23.3%

  • Less cash than profit: free cash flow equal to 58% of net income

Returns

Laboratorios Farmaceuticos Rovi returns with dividends

€1,000 invested in Laboratorios Farmaceuticos Rovi 5 years ago, on November 22, 2021, would be worth €1,128 today with dividends reinvested: +12.82% in total, +2.45% per year. On price alone it would be €1,026 (+2.60%).

PeriodLaboratorios Farmaceuticos RoviIBEX 35€1,000 becomes
1 month+7.50%−1.15%€1,075
6 months+5.25%+4.55%€1,053
Year to date−0.63%+9.04%€994
1 year+11.48%+18.04%€1,115
3 years+26.99%+91.82%€1,270
5 years+12.82%+113.95%€1,128
10 years+537.56%+119.08%€6,376

Over the last 6 months it has done better than 22% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment

The chart in detail

Laboratorios Farmaceuticos Rovi: technical analysis

Laboratorios Farmaceuticos Rovi shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 31.0% below its all-time closing high (€91.50, May 24, 2024).

Trend
No clear trend
RSI (14 sessions)
43
Between 30 and 70
vs 200-session average
−3.91%

Support and resistance

Price areas where Laboratorios Farmaceuticos Rovi has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€71.15+12.76%2 touches, last on November 12, 2026
  2. Last price€63.10
  3. Support€60.90−3.49%2 touches, last on September 29, 2026
  4. Support€59.83−5.19%4 touches, last on October 15, 2026
  5. Support€57.25−9.27%7 touches, last on October 19, 2026

Volatility and risk

Over the last year it has moved little with the IBEX 35.

Beta (1 year) vs IBEX 35
0.39
Volatility (60 sessions, annualised)
27.3%
Largest fall in the last year
−37.29%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Laboratorios Farmaceuticos Rovi: seasonality

Average monthly price change over 19 years

+2.5%Jan+3.3%Feb+0.7%Mar+2.2%Apr−2.4%May+1.8%Jun+0.3%Jul+1.7%Aug−1.1%Sep+1.4%Oct+1.6%Nov+1.3%Dec

Over the last 19 years, the strongest month for Laboratorios Farmaceuticos Rovi has been February: +3.33% on average, positive in 13 years out of 19. The weakest has been May: −2.36% on average, positive in 11 years out of 19. November, the current month, has been positive in 10 years out of 18 (+1.60% on average).

Show chart data
MonthAverageMedianPositive years
January+2.51%+2.88%12 of 19
February+3.33%+3.66%13 of 19
March+0.68%−0.74%9 of 19
April+2.24%+0.10%10 of 19
May−2.36%+0.41%11 of 19
June+1.78%+1.61%11 of 19
July+0.34%+1.21%12 of 19
August+1.75%+1.93%12 of 19
September−1.06%−1.70%7 of 19
October+1.45%+0.91%12 of 19
November+1.60%+2.03%10 of 18
December+1.31%0.00%8 of 18

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Laboratorios Farmaceuticos Rovi and its competitors

Rovi's prescription medicines, including Ameride, Exxiv, Neparvis and Mysimba, form the core of its activity, and the group also sells hospital products such as contrast agents and catheter care under the Fibrilin name. Its portfolio spans cardiology, women's health, anaesthesia and pain, the central nervous system, urology, endocrinology and respiratory care. Beyond its own brands, the company runs contract manufacturing for injectable forms, covering sterile filling, labelling, serialisation and packaging, and it also makes low-molecular-weight heparin.

Headquarters
Pozuelo de Alarcón, Spain
Employees
1,950
Founded
1946
Chief executive
Juan Lopez-Belmonte Encina
Laboratorios Farmaceuticos Rovi and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Laboratorios Farmaceuticos RoviROVI$3.68B20.2%16.0+5.25%
Siegfried HoldingSFZN$3.4B16.7%16.7−19.46%
AlmirallALM$2.45B9.6%30.2−9.84%
FagronFAGR$1.97B14.3%19.5−0.20%
Faes FarmaFAE$1.65B13.0%17.9+4.66%
H. LundbeckHLUN.A$8.56B24.4%14.4+63.06%

Same industry or related industries, similar size. Compare Laboratorios Farmaceuticos Rovi with its competitors · Full profile